Impact of Time and Mechanical Ventilation on Convalescent Plasma in Severe/Critically Ill COVID-19 Patients

Background: Convalescent plasma (CP) transfusion is one of the suggested treatments for Coronavirus disease 2019 (COVID-19) especially in critically ill patients. Objectives: This study aimed to investigate the efficacy and safety of CP transfusion were investigated in severe/critically ill COVID-19 patients. Methods: This study was performed on 50 consecutive COVID-19 patients with severe/critically ill disease. Severe disease was defined as having at least one of the following symptoms: shortness of breath, respiratory frequency ≥ 20/min, blood oxygen saturation ≥ 93%, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, lung infiltrates > 50% within the last 24-48 h. Critically ill disease was identified by intensive care unit admission, respiratory failure, septic shock, or multiple organ dysfunction or failure. Primary outcomes included the safety of CP transfusion, 14-day and 30-day survival rate, and change in lung computed tomography (CT) scan score. Several other clinical and laboratory features were evaluated as the secondary outcomes. Results: Based on the results, 21 out of 50 consecutive patients were on mechanical ventilation at the time of CP transfusion. In total, 32 patients (64%) survived 30 days after CP transfusion. The survival rates were 74% and 44% in patients who received CP < 7 and ≥ 7 days after admission, respectively. While 92% of patients without mechanical ventilation survived, the survival rate of patients on mechanical ventilation was 29%. Moreover, the CT scan score and some other clinical features were improved in the group that received CP transfusion, and no adverse effects were observed. Conclusion: The CP transfusion is a safe and effective treatment in severe/critically ill COVID-19 patients. The best outcome can be achieved in patients who are not on mechanical ventilation, especially early in the disease course.

Impact of time and mechanical ventilation on convalescent plasma in severe/critically ill COVID-19 patients

Background: Convalescent plasma (CP) transfusion is one of the suggested treatments for Coronavirus disease 2019 (COVID-19) especially in critically ill patients. Objectives: This study aimed to investigate the efficacy and safety of CP transfusion were investigated in severe/critically ill COVID-19 patients.

Comparison of Clinical Characteristics, Laboratory Findings and Imag-ing Manifestations of COVID-19 in Sulfur Mustard-exposed Survivors and Others: a Case-control Study

Objective: The objective of this study is to determine if previous exposure to sulfur mustard (SM) gas increases the pathogenesis of COVID-19 by comparing clinical characteristics, laboratory findings, and imaging data between SM-exposed survivors and other patients with COVID-19. Methods: This case-control study was conducted in Baqiyatallah hospital, Tehran, Iran, from 26th Feb - 26th March 2020. The case group composed of 60 SM-exposed survivors infected with COVID-19, and the control group was composed of 60 patients with COVID-19. Groups were matched for demographic (including age and gender) and comorbidity variables except for lung disease which was higher in the case group. The clinical characteristics, laboratory findings, and imaging manifestations, as well as outcomes, were compared between the two groups. Results: While the majority of patients in the case and control groups had at least one comorbidity like diabetes, hypertension, or heart disease, only lung disease was significantly higher in the case than in the control group (P=0.001). Patients in both groups displayed a variety of symptoms on arrival. Only chest pain was significantly more frequent in case patients than those in the control group. The levels of Neutrophils, ESR, BS, AST, LDH, and CRP in both groups were higher, and Na levels were lower than the normal range. Neutrophils were significantly higher in the case than in the control group (p=0.02). The BUN level was significantly lower in the control than in the case group (p=0.04). Other laboratory findings were within their normal ranges and similar in both groups. Significantly more patients in the case group showed early-stage opacities than those in the control group (p=.03). There were no significant differences in treatment or outcomes between the two groups. Conclusion: Most clinical characteristics, outcomes, and laboratory findings of COVID-19 in SMexposed survivors, were similar to those in the non-exposed. While these findings suggest that sulfur mustard gas exposure does not significantly affect the prognosis of the disease, the limitations and sample size of the current study may warrant additional investigations.